

IN THE CLAIMS:

Kindly replace claims 1, 3-5, 9, and 22 with the following new claims. An Appendix showing all changes to the claims is attached to this amendment as required by 37 CFR § 1.121(c).

B¹⁴
1. (Twice amended) A composition for the inhibition of tumorigenesis comprising a pharmaceutical carrier and an antisense nucleic acid comprising at least 15 nucleotides hybridizable in a cell to at least a portion of an RNA transcript of a Nr-CAM gene of SEQ ID NO: 1 in an amount effective to inhibit tumorigenesis by inhibiting hyperproliferation of a human tumor cell having high Nr-CAM expression.

B¹⁷
3. (Twice amended) A method of inhibiting proliferation of a human cell expressing Nr-CAM in a subject comprising administering to the subject an effective amount of a Nr-CAM antisense nucleic acid comprising at least 15 nucleotides that inhibits Nr-CAM expression, wherein the Nr-CAM antisense nucleic acid is hybridizable in the cell to at least a portion of a RNA transcript of the Nr-CAM gene of SEQ. ID. NO.: 1.

B¹⁸
4. (Amended) The method according to claim 3 in which the human cell expressing Nr-CAM is involved with a malignancy.

B¹⁹
5. (Amended) The method according to claim 4 in which the malignancy is selected from the group consisting of brain cancer, leukemia, and B cell lymphoma.

B²⁰
9. (Amended) The method according to claim 3 in which the human cell expressing Nr-CAM is involved with a disease or disorder selected from the group consisting of premalignant conditions, benign tumors, hyperproliferative disorders, and benign dysproliferative disorders.

B²¹
22. (Amended) The composition of claim 1, wherein the composition is formulated as a liquid.

Please add the following claims:

1
23. (New) The method of claim 3, wherein the Nr-CAM antisense nucleic acid is administered locally.

1
24. (New) The method of claim 23, wherein the local administration is by direct injection.

1 25. (New) The method of claim 4, wherein the Nr-CAM antisense nucleic
2 acid is administered locally by direct injection at the site or former site of a tumor.

1 26. (New) The method of claim 25, wherein the administration is
2 intratumoral.

1 27. (New) The method of claim 3, wherein the human cell expressing Nr-
2 CAM is a tumor cell of the central nervous system and the administration is intraventricular or
3 intrathecal.

1 28. (New) The composition of claim 23, wherein the tumor cell is a human
2 glioblastoma cell.

1 29. (New) The composition of claim 23, wherein the isolated nucleic acid
2 comprises at least 15 nucleotides corresponding to a portion of SEQ ID NO: 1 that is within
3 nucleotides 119 to 2746.

1 30. (New) The composition of claim 23, wherein the isolated nucleic acid
2 comprises at least 15 nucleotides corresponding to a contiguous portion of SEQ ID NO:1 that
3 is within nucleotides 119 to 1434.

1 31. (New) An isolated nucleic acid comprising at least 15 nucleotides, the
2 isolated nucleic acid hybridizable, under highly stringent conditions comprising hybridization
3 in an aqueous solution containing 6X SSC at 65° C, to at least a portion of a messenger RNA
4 having SEQ ID NO: 1 and encoding human Nr-CAM, wherein the oligonucleotide inhibits the
5 expression of Nr-CAM in a tumor cell.

1 32. (New) A method for inhibiting the migratory activity of a tumor cell
2 expressing Nr-CAM in a subject comprising administering to the subject an effective amount
3 of a Nr-CAM antisense nucleic acid comprising at least 15 nucleotides that inhibits Nr-CAM
4 expression, wherein the Nr-CAM antisense nucleic acid is hybridizable in the cell to at least a
5 portion of a RNA transcript of the Nr-CAM gene of SEQ. ID. NO.: 1.

1 33. (New) A method for inhibiting the ability of a tumor cell expressing Nr-
2 CAM to invade the extracellular matrix in a subject comprising administering to the subject an
3 effective amount of a Nr-CAM antisense nucleic acid comprising at least 15 nucleotides that
4 inhibits Nr-CAM expression, wherein the Nr-CAM antisense nucleic acid is hybridizable in the
5 cell to at least a portion of a RNA transcript of the Nr-CAM gene of SEQ. ID. NO.: 1.